Physician profile
Benjamin James Epstein
NPI 1205295409
$447,320.20
in general payments reported to CMS, 2019-2025
38 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16K · 2022: $36K · 2023: $105K · 2024: $150K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $162K · Consulting Fee: $124K · Travel and Lodging: $54K · Honoraria: $29K · Food and Beverage: $25K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $161,597.50 |
| Consulting Fee | $123,795.50 |
| Travel and Lodging | $54,236.86 |
| Honoraria | $29,413.00 |
| Food and Beverage | $24,554.24 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,872.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $177,133.03 | 2022-2025 | Auvelity, Sunosi |
| Abbvie INC. | $103,842.38 | 2021-2025 | |
| Alkermes, INC. | $74,825.42 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Collegium Pharmaceutical, INC. | $19,231.52 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15,857.54 | 2021-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $12,648.66 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $12,596.57 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $8,475.21 | 2021-2024 | Jornay Pm |
| Neos Therapeutics, LP | $5,779.38 | 2021-2025 | Adzenys Xr-Odt, Exxua, Cotempla Xr-Odt |
| Neurocrine Biosciences, INC. | $3,054.26 | 2021-2025 | Ingrezza |
| Noven Pharmaceuticals, INC. | $2,129.93 | 2024 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $1,550.14 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $1,319.15 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Aytu Biopharma, INC. | $1,300.00 | 2025 | |
| Bausch Health US, LLC | $821.84 | 2021-2025 | Wellbutrin, Aplenzin |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $782.47 | 2021-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $768.95 | 2021-2025 | Trintellix |
| Lundbeck LLC | $761.03 | 2021-2025 | Rexulti |
| Corium, LLC | $622.74 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $601.76 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $582.83 | 2021-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $495.97 | 2021-2025 | Uzedy, Austedo |
| Noven Therapeutics, LLC | $478.79 | 2022-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $346.82 | 2021 | |
| Almatica Pharma LLC | $249.92 | 2021-2024 | Loreev Xr |
| Eisai INC. | $212.03 | 2021 | |
| Tris Pharma INC | $194.99 | 2021-2025 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $186.87 | 2021-2022 | |
| Indivior INC. | $92.15 | 2023-2024 | Perseris, Sublocade |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $89.72 | 2024-2025 | Rejoyn, Abilify Maintena, Rexulti |
| Jazz Pharmaceuticals INC. | $59.15 | 2021-2022 | |
| Owp Pharmaceuticals, INC. | $57.64 | 2021-2022 | |
| Adlon Therapeutics L.P. | $51.47 | 2021 | |
| Alfasigma USA, INC. | $30.50 | 2021 | |
| Currax Pharmaceuticals LLC | $28.44 | 2021-2022 | |
| Sage Therapeutics, LLC | $23.48 | 2022 | |
| Merck Sharp & Dohme LLC | $20.65 | 2021 | |
| Lilly USA, LLC | $16.80 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.